A Phase 2, Open-label Study of MAC-321 Administered Intravenously as a Single Agent for the Treatment of Non-small Cell Lung Cancer Refractory to Platinum-based Therapy

Inclusion Criteria:

- Recurrence of non-small cell lung cancer after at least 1 prior chemotherapy regimen
containing a platinum agent

- Recovery from all acute side effects of prior therapies (with the exception of hair
loss)

- Adequate bone marrow, liver, and kidney function

Exclusion Criteria:

- More than 2 prior chemotherapy regimens for treatment of advanced or metastatic
non-small cell lung cancer. (Treatment given in conjunction with surgery will not be
included in the maximum of 2 prior regimens)

- Radiation therapy, chemotherapy or any other anticancer therapy within 28 days of
beginning study

- Symptomatic brain metastases